Related Experiment Video
Updated: May 16, 2026
A Swine Model of Neonatal Asphyxia
Published on: October 11, 2011
Neuroprotective treatment for perinatal asphyxia
Anne Lee Solevåg1, Britt Nakstad
1Department of Child and Adolescent Medicine, Akershus University Hospital, Norway. a.l.solevag@medisin.uio.no
Insights
Perinatal asphyxia can cause severe harm, but interventions during the latent phase (6-24 hours post-hypoxia) can limit neurological damage. Hypothermia is the only proven treatment, while xenon, erythropoietin, and allopurinol show promise.
Area of Science:
- Neonatal neurology
- Neuroprotection strategies
- Perinatal medicine
Background:
- Perinatal asphyxia poses significant risks to newborns, potentially leading to severe illness or death.
- The latent phase, occurring 6-24 hours post-hypoxic event, presents a critical window for intervention.
- Limiting neurological damage during this phase is crucial for improving infant outcomes.
Purpose of the Study:
- To review established and promising neuroprotective treatments for perinatal asphyxia.
- To identify interventions targeting cellular mechanisms of neurological damage.
- To evaluate strategies for limiting brain injury after hypoxic events.
Main Methods:
- Comprehensive literature search of Medline and Cochrane Library databases.
- Selection of 44 indexed, peer-reviewed original articles in English.
- Focus on neuroprotective treatment strategies for perinatal asphyxia.
Main Results:
- Hypothermia is the only treatment demonstrated to improve long-term outcomes in randomized clinical trials.
- Several potential treatments, including xenon gas, erythropoietin, and allopurinol, are currently under clinical investigation.
- Various treatments target diverse cellular mechanisms contributing to hypoxic-ischemic brain injury.
Conclusions:
- Further research is needed to assess the efficacy of xenon, erythropoietin, and allopurinol, particularly in combination with hypothermia.
- Future therapeutic avenues may include antioxidants, stem cell treatments, and DNA repair mechanisms.
- Optimizing neuroprotection in the latent phase holds potential for improved neurological recovery.
Background:
Perinatal asphyxia can cause serious illness or death. By taking steps in the «latent phase», which occurs 6-24 hours after the hypoxic event, the neurological damage caused by perinatal asphyxia can be limited. We wish to present a selection of such measures that are either established treatment today or that appear promising.
Method:
We searched in the Medline and Cochrane Library databases for options for treating perinatal asphyxia.
Results:
An overwhelming number of potential treatments were identified. From among them we selected 44 indexed, peer-reviewed original articles in English on strategies for neuroprotective treatment after perinatal asphyxia. The treatments target different cellular mechanisms that cause neurological damage following perinatal asphyxia. In randomised clinical trials, only hypothermia treatment has improved the long-term outcome for newborns with perinatal asphyxia. Xenon gas, erythropoeitin and allopurinol are undergoing clinical testing.
Interpretation:
The efficacy of xenon gas, erythropoeitin and allopurinol in combination with the established treatment form of hypothermia must be studied more closely. Antioxidants, stem cell treatment and DNA repair mechanisms can pave the way for new opportunities in the future.
